Compare Cytokinetics Inc (CYTK) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wix.Com Ltd — how do they compare? Cytokinetics Inc trades at $62.73 (market cap $8.62B), while Wix.Com Ltd trades at $75.88 (market cap $3.11B). The key difference: Cytokinetics Inc is far larger — about 2.8× Wix.Com Ltd's market cap, and Wix.Com Ltd is more actively traded (809,286 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Wix.Com Ltd for 62 Days on average.
| CYTK | WIX | |
|---|---|---|
Market Cap | $8.62B | $3.11B |
Volume | 2,594,626 | 809,286 |
Sector | Health | Technology |
52-Week High | $87.26 | $145.54 |
52-Week Low | $54.76 | $40.43 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $8.72B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Wix.com (WIX) trades at $72.97, down 1.27% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth reaching $1.99B in 2025, though net income margin remains negative at -8.19%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. Multiple class action lawsuits filed in September 2026 create significant legal overhang.
While analyst consensus remains bullish with 63% buy ratings and $77 price target, the combination of negative cash flow trends, legal challenges, and high valuation multiples (P/E 62.84) presents substantial risk. The stock faces headwinds from operational execution challenges despite solid revenue growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
